MX2022008060A - Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. - Google Patents

Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma.

Info

Publication number
MX2022008060A
MX2022008060A MX2022008060A MX2022008060A MX2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A MX 2022008060 A MX2022008060 A MX 2022008060A
Authority
MX
Mexico
Prior art keywords
variant
hyaluronic acid
pharmaceutical composition
same
improved stability
Prior art date
Application number
MX2022008060A
Other languages
English (en)
Inventor
Soon Jae Park
Hyung- Nam Song
Hye- Shin CHUNG
Seung Joo Lee
Kyuwan Kim
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of MX2022008060A publication Critical patent/MX2022008060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02001—Hyaluronate lyase (4.2.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se divulgan nuevas variantes de PH20 o fragmentos de las mismas con estabilidad térmica y actividad enzimática mejoradas de la hialuronidasa humana, que es una enzima que hidroliza el ácido hialurónico, y más particularmente nuevas variantes de PH20 o fragmentos de las mismas que incluyen una o más sustituciones de residuos de aminoácidos en la variante que tiene la secuencia de aminoácidos de SEQ ID NO: 3, en la que uno o más residuos de aminoácidos en el N-terminal y/o en el C-terminal se eliminan opcionalmente.
MX2022008060A 2020-01-23 2021-01-25 Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma. MX2022008060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200009046 2020-01-23
PCT/KR2021/000943 WO2021150079A1 (ko) 2020-01-23 2021-01-25 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
MX2022008060A true MX2022008060A (es) 2022-07-27

Family

ID=76992900

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008060A MX2022008060A (es) 2020-01-23 2021-01-25 Nuevas variantes de hialuronidasa con estabilidad mejorada y composicion farmaceutica que contiene la misma.

Country Status (12)

Country Link
US (3) US12618055B2 (es)
EP (1) EP3992285A4 (es)
JP (3) JP2022552756A (es)
KR (2) KR102801434B1 (es)
CN (5) CN120699939A (es)
AU (2) AU2021211348B2 (es)
BR (1) BR112021022739A2 (es)
CA (1) CA3137324A1 (es)
MX (1) MX2022008060A (es)
TW (3) TW202615652A (es)
WO (1) WO2021150079A1 (es)
ZA (1) ZA202206370B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
TW202615652A (zh) 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
WO2023042096A1 (en) 2021-09-14 2023-03-23 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR102774438B1 (ko) * 2022-06-08 2025-02-27 (주)한국비엠아이 히알루로니다제 폴리펩티드 및 이의 용도
WO2023249408A1 (ko) * 2022-06-22 2023-12-28 (주)알테오젠 N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
KR102976805B1 (ko) * 2023-06-26 2026-06-15 주식회사 오디스젠 신규 인간 히알루로니다제 Hyal1 변이체
JP7894954B2 (ja) * 2022-06-29 2026-07-24 オディスジェン インコーポレイテッド 中性ｐＨで活性を示すヒアルロニダーゼＨＹＡＬ１変異体
KR102621518B1 (ko) * 2022-06-29 2024-01-10 주식회사 오디스젠 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도
KR20250134732A (ko) 2022-12-22 2025-09-11 할로자임, 아이엔씨 대용량 투여를 위한 히알루로니다아제 효소 제형
WO2024196173A1 (ko) * 2023-03-23 2024-09-26 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
KR102875495B1 (ko) * 2023-12-28 2025-10-27 주식회사 오디스젠 히알루로니다제 Hyal1 변이체
WO2025188901A1 (en) 2024-03-05 2025-09-12 Halozyme, Inc. Combination therapy with antibody-drug conjugates and hyaluronidases
TW202617771A (zh) 2024-06-21 2026-05-01 美商艾普吉醫療股份有限公司 結合ｉｌ－１３之抗體及結合ｏｘ４０ｌ之抗體
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2026085415A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
WO2026085417A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085414A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085419A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
WO2026120486A1 (en) 2024-12-02 2026-06-11 Halozyme, Inc. Soluble hyaluronidase and production thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
FR2805330B1 (fr) 2000-02-23 2002-11-29 Manuli Auto France Ensemble de connexion entre un embout de tube rigide cylindrique coude a son extremite et une piece, et procede de raccordement correspondant
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
RU2008123518A (ru) 2005-11-10 2009-12-20 Ресептор Байолоджикс, Инк. (Us) Способы получения изоформ рецепторов и лигандов
WO2009037566A2 (en) 2007-06-19 2009-03-26 Uvarkina Tamara P Hyaluronidase and method of use thereof
ITMI20072225A1 (it) 2007-11-23 2009-05-24 Luso Farmaco Inst "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
CN101970650B (zh) 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
ES2573462T3 (es) 2008-12-09 2016-06-08 Halozyme, Inc. Polipéptidos de PH20 soluble extendida y usos de los mismos
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2010138918A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2013202020B2 (en) 2009-07-31 2014-11-27 F. Hoffmann-La Roche Ag Subcutaneous anti-HER2 antibody formulation
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
EP2720712B1 (en) 2011-06-17 2016-03-02 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
CN103173474B (zh) 2013-03-27 2014-08-27 广州白云山拜迪生物医药有限公司 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列
US9515094B2 (en) 2013-06-26 2016-12-06 Semiconductor Energy Laboratory Co., Ltd. Storage device and semiconductor device
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
AU2014350208B2 (en) 2013-11-13 2017-09-07 Tillotts Pharma Ag Multi-particulate drug delivery system
JP2015095423A (ja) 2013-11-14 2015-05-18 Fdk株式会社 リチウム二次電池用電極材料およびリチウム二次電池
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
US20170218382A1 (en) 2014-07-31 2017-08-03 National University Corporation Kobe University Secretion Signal Peptide, And Protein Secretory Production And Cell Surface Display Using Said Secretion Signal Peptide
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
JP2018052818A (ja) 2015-01-28 2018-04-05 武田薬品工業株式会社 スルホンアミド化合物
CN104745553B (zh) 2015-03-27 2017-11-28 杭州北斗生物技术有限公司 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法
CA2896038C (en) 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CN105567606B (zh) 2016-03-02 2019-03-19 青岛海洋生物医药研究院股份有限公司 一种球形节杆菌及其产生的透明质酸酶
EP3548096B1 (en) 2016-11-30 2024-11-20 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060695A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
MX2020009824A (es) * 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN115279766B (zh) 2020-01-03 2025-05-02 因赛特公司 包含a2a/a2b和pd-1/pd-l1抑制剂的组合疗法
TW202615652A (zh) 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
JP7252150B2 (ja) 2020-02-04 2023-04-04 トヨタ自動車株式会社 車両制御装置、車両制御システム、及び車両制御プログラム
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
US20230365692A1 (en) 2020-09-24 2023-11-16 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
JP2022066832A (ja) 2020-10-19 2022-05-02 トヨタ自動車株式会社 車載エンジンの制御装置
JP7465797B2 (ja) 2020-12-15 2024-04-11 株式会社日立製作所 リザーバー計算機
CA3236277A1 (en) 2021-10-29 2023-05-04 Soon Jae Park Pharmaceutical composition comprising human hyaluronidase ph20 and drug
JP2024025989A (ja) 2022-08-15 2024-02-28 国立大学法人秋田大学 直流磁場測定方法および直流磁場測定装置、ならびに交流磁場測定方法および交流磁場測定装置
JP7559016B2 (ja) 2022-08-15 2024-10-01 キヤノン株式会社 基板接合体の製造方法、液体吐出基板の製造方法、基板接合体、及び液体吐出基板
TWI887800B (zh) 2022-10-12 2025-06-21 美商默沙東有限責任公司 經由皮下投予抗pd1抗體以治療癌症之組合物及方法
JP2024081276A (ja) 2022-12-06 2024-06-18 オムロン株式会社 ホイールユニットおよびこれを備えたマウス
JP2024081274A (ja) 2022-12-06 2024-06-18 トヨタ自動車株式会社 車両周辺監視装置、車両周辺監視方法及び車両周辺監視プログラム

Also Published As

Publication number Publication date
AU2024200091A1 (en) 2024-01-25
ZA202206370B (en) 2023-06-28
US20260193633A1 (en) 2026-07-09
CA3137324A1 (en) 2021-07-29
JP2026094192A (ja) 2026-06-09
US20230250408A1 (en) 2023-08-10
KR102801434B1 (ko) 2025-04-30
TW202140780A (zh) 2021-11-01
JP7820431B2 (ja) 2026-02-25
WO2021150079A1 (ko) 2021-07-29
CN120699939A (zh) 2025-09-26
JP2024095673A (ja) 2024-07-10
KR20220069045A (ko) 2022-05-26
BR112021022739A2 (pt) 2022-08-09
US12618055B2 (en) 2026-05-05
CN120966799A (zh) 2025-11-18
CN121450619A (zh) 2026-02-03
CN121472194A (zh) 2026-02-06
TWI910131B (zh) 2026-01-01
US20260193632A1 (en) 2026-07-09
AU2021211348B2 (en) 2023-10-05
JP2022552756A (ja) 2022-12-20
TW202615652A (zh) 2026-04-16
AU2021211348A1 (en) 2021-12-09
EP3992285A1 (en) 2022-05-04
CN113840921A (zh) 2021-12-24
TW202302845A (zh) 2023-01-16
KR20250065714A (ko) 2025-05-13
TWI921605B (zh) 2026-04-11
EP3992285A4 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
AU2019311658A8 (en) Novel hyaluronidase variants and pharmaceutical composition comprising the same
MY204342A (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
BR112021022739A2 (pt) Variante de ph20 ou fragmento, método de produção e composição para tratar câncer compreendendo a variante ou fragmento da mesma
NZ597306A (en) Mesenchymal stem cell differentiation
WO2021000968A3 (zh) 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
ES2566740T3 (es) Vacunas y agentes terapéuticos de GAS en combinación
NZ595063A (en) Polypeptides from neisseria meningitidis
ZA202404727B (en) N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof
JP7699196B2 (ja) ブタトリプシンの変異体
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
JP2020037538A5 (es)
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
KR102565312B1 (ko) 활성화된 클로스트리디움 신경독소의 생산
WO2023144753A3 (en) Recombinant expression of fumonisin esterase, compositions and uses thereof
WO2023102407A3 (en) Engineered high activity omni-79 nuclease variants
WO2019219903A3 (en) Mutant lipase and use thereof
WO2025077943A3 (zh) TST3b蛋白质及其相关生物材料在调控番茄可溶性糖含量中的应用
ZA202404498B (en) Recombinant protein for sars-cov2 disease
MX2020010422A (es) Alfa-amilasa maltogenica variante.
MX2025009803A (es) PROTEÍNA DE FUSIÓN QUE COMPRENDE FRAGMENTO DE LA REGIÓN EXTRACELULAR DE TGF-ßRII, COMPOSICIÓN FARMACÉUTICA DE LA MISMA Y USO DE LA MISMA
WO2021207706A3 (en) Methods and compositions for inactivating interleukin-2-inducible t-cell kinase (itk)
JP2018143142A5 (es)
MX2021014268A (es) Proteina optimizada que comprende los aminoacidos esenciales para la nutricion humana.
MX2024009427A (es) Fragmento c-terminal de apolipoproteina e y aplicacion del mismo en la inhibicion de la actividad de \03b3-secretasa.
ZA202400096B (en) Recombinant proteins, compositions and methods of stabilization thereof